Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden.
Michelle L M MulderTamara W van HalFrank H J van den HoogenElke M G J de JongJohanna E VriezekolkMark H WeninkPublished in: Rheumatology (Oxford, England) (2021)
PASDAS implementation uncovered relevant residual disease activity in a quarter of patients previously assessed as being in DAS28 VLDA/LDA, underscoring the potential value of PASDAS measurements in PsA clinical care.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- healthcare
- juvenile idiopathic arthritis
- end stage renal disease
- quality improvement
- primary care
- newly diagnosed
- prostate cancer
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- palliative care
- radical prostatectomy
- pain management